ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.20
-0.38 (-2.05%)
At close: 4:00PM EST

18.29 +0.09 (0.51%)
After hours: 4:26PM EST

Stock chart is not supported by your current browser
Previous Close18.58
Open18.43
Bid18.23 x 900
Ask19.95 x 800
Day's Range18.12 - 18.60
52 Week Range17.11 - 37.75
Volume1,172,717
Avg. Volume1,630,587
Market Cap2.867B
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference

    Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00 p.m. ET/5:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT).The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

  • PR Newswire

    Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar I disorder. ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The ALKS 3831 NDA includes data from the ENLIGHTEN clinical development program in patients with schizophrenia, as well as pharmacokinetic (PK) bridging data comparing ALKS 3831 and ZYPREXA® (olanzapine).

  • PR Newswire

    Alkermes to Acquire Rodin Therapeutics

    DUBLIN and BOSTON, Nov. 18, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. This transaction builds on Alkermes' experience in central nervous system (CNS) diseases and expands Alkermes' CNS development efforts into a wide range of neurodegenerative disorders.

  • PR Newswire

    Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

    DUBLIN , Nov. 12, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov. 19, 2019 ...

  • PR Newswire

    Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

    DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis, and Alkermes' transfer to Biogen Inc. (BIIB) of the New Drug Application and other regulatory documentation related to VUMERITY. "The receipt of this milestone payment marks an important achievement for Alkermes and is a testament to the strategic execution of our clinical and regulatory activities related to VUMERITY over the past few years. This payment bolsters our solid financial foundation and increases our flexibility to pursue strategic business development opportunities and invest in our internal development pipeline," commented Blair Jackson, Senior Vice President of Corporate Planning.

  • PR Newswire

    Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

    ̶ Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab ̶ ̶ Posters and a Corporate Presentation ...

  • PR Newswire

    Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

    - Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 - DUBLIN , Nov. 4, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from ...

  • GlobeNewswire

    Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    Biogen Inc. (BIIB) and Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive, worldwide license to commercialize VUMERITY and intends to make it available in the United States in the near future. “The FDA’s approval of VUMERITY delivers on Biogen’s commitment to pursue new therapies that may provide meaningful impact for people living with relapsing MS, and we look forward to bringing it to the MS community as an additional treatment option,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president, research and development, and chief medical officer at Biogen.

  • PR Newswire

    Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

    -- Third Quarter Revenues of $255.2 Million , Primarily Driven by Approximately 20% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.34 and Non-GAAP ...

  • PR Newswire

    Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

    DUBLIN, Oct. 21, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230, Alkermes' immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The planned phase 2 multi-site trial, ION-01, is designed to estimate the response rate to ALKS 4230 in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced or recurrent head and neck squamous cell cancer who did not achieve complete remission with an anti-PD-(L)1 antibody treatment.

  • PR Newswire

    Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

    DUBLIN , Oct. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, October 23, 2019 , to discuss the ...

  • PR Newswire

    Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

    -- Findings From Patient Surveys Underscore Need for New Antipsychotic Treatments With Reduced Side Effects -- DUBLIN , Oct. 7, 2019 /PRNewswire/ --   Alkermes plc  (Nasdaq: ALKS) today announced the  presentation ...

  • PR Newswire

    Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

    DUBLIN , Sept. 26, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, ...

  • PR Newswire

    Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

    DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today. Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine.

  • GlobeNewswire

    Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

    Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate).

  • PR Newswire

    Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

    Under the agreement, the parties agreed to request termination of the IPR and Alkermes granted Amneal the non-exclusive right to market a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Additional terms of the agreement are confidential.

  • PR Newswire

    Alkermes Plc Reports Second Quarter 2019 Financial Results

    -- Second Quarter Revenues of $279.9 Million , Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.27 and Non-GAAP ...

  • PR Newswire

    Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results

    DUBLIN , July 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, July 25, 2019 , to discuss the company's ...

  • PR Newswire

    Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

    DUBLIN, July 15, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today provided an update on its regulatory strategy for ALKS 3831 (olanzapine/samidorphan), the company's investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. Following a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company plans to expand the NDA for ALKS 3831 to encompass the treatment of bipolar I disorder in addition to the treatment of schizophrenia.

  • PR Newswire

    Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History

    WALTHAM, Mass., July 1, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that for the 11th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater Boston area as part of what was the company's largest-ever annual day of service – Alkermes in Action. On Thursday, June 27, more than 450 Alkermes employees volunteered to work on various activities supporting 15 local nonprofits that are aligned with the company's values as a corporate citizen.

  • PR Newswire

    Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

    -- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune ...

  • GlobeNewswire

    New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

    Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.

  • PR Newswire

    Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

    -- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia -- DUBLIN , May 22, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) ...